OCUMENSION THERAPEUTICS
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.
OCUMENSION THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2017-01-01
Status:
Active
Contact:
+86 (021)-61493800
Email Addresses:
[email protected]
Total Funding:
200 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Content Delivery Network Euro JsDelivr GStatic Google Static Content Pound Sterling IIS 10 Japanese Yen
Current Employees Featured
Stock Details
Investors List
General Atlantic
General Atlantic investment in Series B - Ocumension Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-04-14 | Alimera Sciences | Ocumension Therapeutics investment in Post-IPO Equity - Alimera Sciences | 20 M USD |
| 2021-01-03 | EyePoint Pharmaceuticals | Ocumension Therapeutics investment in Post-IPO Equity - EyePoint Pharmaceuticals | 15.7 M USD |